Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Lula’s former human rights minister formally accused of sexual misconduct - 2Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
- 3Banks for High Fixed Store Rates: Augment Your Investment funds
- 4Giant ‘toothed’ birds flew over Antarctica 40 million to 50 million years ago
- 5German men need approval for stays abroad under military service law
- A top Marine shares his secrets to keeping fit at 50
- Examination In progress into Abuse of Japanese Government-Supported Advance
- Haifa refinery said hit in latest Iranian missile barrage
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Germany records first wolf bite on human since repopulation
- Genetic study identifies earliest-known dog, dating to 15,800 years ago
- Vote in favor of the bloom plan that adds a bit of excellence to your life!
- Merz: 80% of Syrians in Germany should return in three years
- Intriguing Strange Cruising Objections you Should Visit
